MYND Life Sciences Inc.

MYND

CA62857B1094

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2024-04-22 am EDT			5-day change	1st Jan Change
0.03 ^CAD	0.00%		0.00%	-25.00%

Mar. 21	MYND Life Sciences Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
Mar. 04	MYND Life Sciences Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	CI

MYND Lifesciencs Inc. entered into a non-binding memorandum of understanding to acquire Tidal Psychedelics.

March 15, 2022

MYND Lifesciencs Inc. (CNSX:MYND) entered into a non-binding memorandum of understanding to acquire Tidal Psychedelics on March 16, 2022. Both MYND and Tidal have agreed on an all-share transaction.

Latest news about MYND Life Sciences Inc.

MYND Life Sciences Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 20	CI
MYND Life Sciences Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	Mar. 04	CI
MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive Director	Jan. 30	CI
Mynd Announces Transition of Dr. Lyle Oberg, E.C.A. to Executive Chairman from the Role of CEO	Dec. 06	CI
Mynd Announces Transition of Dr. Lyle Oberg, E.C.A. from the Role of CEO to Executive Chairman	Dec. 06	CI
MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive Officer	Dec. 06	CI
MYND Life Sciences Inc. Appoints John Campbell as President	Dec. 06	CI
MYND Life Sciences Inc. entered into a non-binding letter of intent to acquire Cava Healthcare Inc.	23-10-24	CI
MYND Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-19	CI
MYND Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-28	CI
MYND Life Sciences Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-05-05	CI
MYND Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	23-04-27	CI
MYND Life Sciences Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	23-04-27	CI
MYND Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	22-09-27	CI
VMYND Lifesciencs Inc. cancelled the acquisition of Tidal Psychedelics.	22-06-28	CI
MYND Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022	22-06-23	CI
MYND Life Sciences Inc. Announces New Testing Methodologies for Measuring Cellular Responses to Microdosing with Psilocybins	22-06-01	CI
MYND Lifesciencs Inc. announced that it expects to receive CAD 3.5 million in funding	22-04-20	CI
MYND Lifesciencs Inc. Reports Earnings Results for the First Quarter Ended January 31, 2022	22-03-31	CI
MYND Life Sciences Reports MoU to Buy Tidal Psychedelics	22-03-16	MT
MYND Lifesciencs Inc. entered into a non-binding memorandum of understanding to acquire Tidal Psychedelics.	22-03-15	CI
MYND Lifesciencs Inc. Hires Chaahat S.B Singh as Senior Operations and Research Manager	22-03-09	CI
MYND Lifesciencs Inc. Announces Executive Changes	22-03-09	CI
MYND Lifesciencs Inc. Auditor Raises 'Going Concern' Doubt	22-02-27	CI
MYND Lifesciencs Inc. Reports Earnings Results for the Full Year Ended October 31, 2021	22-02-27	CI

MYND Life Sciences Inc. is a Canada-based medical biotech drug research and development company. The Company is focused on neuro-pharmaceutical drug development, diagnostics and vaccines. It is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio) pharmaceutical companies by molecular concepts for the applications of psilocybin analogs for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property. The Company is engaged in collaborative research with the Michael Smith Laboratories at the University of British Columbia.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MYND LIFE SCIENCES INC.	-25.00%	1.05M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B